Mezzion Secures Key U.S. Patent for Udenafil Benefitting Fontan Patients Mezzion Pharmaceuticals has received a crucial U.S. patent for Udenafil, boosting its exclusivity for Fontan patients and paving the way for future advancements.

Mezzion Secures Key U.S. Patent for Udenafil Benefitting Fontan Patients #United_States #Fort_Lee #Mezzion_Pharmaceuticals #Udenafil #Fontan_Patients

Mezzion Pharma Ventures into ADPKD Market with Udenafil Pipeline Expansion Mezzion Pharma is expanding its udenafil pipeline into ADPKD, targeting a lucrative market for kidney disease treatment, aiming for safer and effective options.

Mezzion Pharma Ventures into ADPKD Market with Udenafil Pipeline Expansion #South_Korea #Seoul #ADPKD #Udenafil #Mezzion_Pharma

Mezzion Pharma Announces $20 Million Funding to Support Udenafil for Fontan Patients' Trials Mezzion Pharmaceuticals secures $20 million in funding to advance development of udenafil, targeting Fontan patients' unmet needs.

Mezzion Pharma Announces $20 Million Funding to Support Udenafil for Fontan Patients' Trials #South_Korea #Seoul #Udenafil #Fontan_Patients #Mezzion_Pharma